Clinical characteristics and survival outcomes of elderly patients with de novo metastatic germ cell tumors

Abstract

ObjectivesTo determine the outcomes for elderly patients with de novo metastatic germ cell tumors and the influence of patient age on adherence to standard chemotherapy.MethodsA total of 150 patients who were initially diagnosed with metastatic germ cell tumors and treated at our institution between 2007 and 2021 were included. Patients were classified according to three age groups: aged <40, 40–49, and ≥50 years. Clinicopathological features, adherence to standard first‐line chemotherapy, overall survival, and disease‐free survival were compared between these groups. We also analyzed the outcomes of patients who received low‐intensity induction chemotherapy due to adverse events and/or comorbidities.ResultsThere was no significant difference in any of the survival outcomes and in the rate of adherence to standard first‐line chemotherapy between the three age groups, although elderly patients with intermediate/poor prognosis group tended to receive less‐intense chemotherapies. The rate of febrile neutropenia as a chemotherapy‐related adverse event was significantly higher in patients aged ≥50 years. No statistical significance in survival outcomes was detected between the group of patients who received relatively low‐intensity induction chemotherapy and those who received adequately intensive planned chemotherapy.ConclusionsThe adherence rate of standard fist‐line chemotherapy of elderly patients is almost comparable to that of younger patients, although some adverse events should be carefully managed. Even elderly patients with metastatic germ cell tumors can aim for equivalently good survival outcome like younger populations, with effort to adhere to standard chemotherapy.